The drug will target specific genetic mutations prevalent in certain types of cancers
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Total transaction value of the divestment is Rs. 3,660 million
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Subscribe To Our Newsletter & Stay Updated
